Actionnariat et activité des initiés pour BioXcel Therapeutics, Inc. (BTAI): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $0.07 |
| Capitalisation | $2M |
| Bourse | NASDAQ |
| Pays | US |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | 0 | $887000 | $42.6M | $32.4M | $213.1M | $233.0M | $193.7M | $65.2M | $29.9M | $28.4M |
| Placements à Court Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Créances | 0 | 0 | $115000 | 0 | 0 | 0 | $248000 | $71000 | $131000 | $233000 |
| Stocks | 0 | 0 | 0 | 0 | 0 | 0 | $2.0M | $2.0M | $679000 | $722000 |
| Actifs Courants | $2000 | $890000 | $43.2M | $34.1M | $217.1M | $236.8M | $202.9M | $72.1M | $37.4M | $44.7M |
| Immobilisations Corporelles | $5000 | $4000 | $327000 | $2.2M | $2.8M | $2.5M | $2.1M | $1.5M | $857000 | $231000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Incorporels | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Totaux | $7000 | $1.4M | $43.5M | $36.4M | $219.9M | $239.4M | $205.9M | $73.7M | $38.3M | $44.9M |
| Dettes Fournisseurs | $279000 | $444000 | $1.6M | $5.0M | $4.0M | $4.7M | $10.2M | $13.7M | $16.0M | $14.7M |
| Dette à Court Terme | 0 | $371000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $24.9M |
| Passifs Courants | $331000 | $2.3M | $4.7M | $8.5M | $11.8M | $16.7M | $32.9M | $27.3M | $22.2M | $53.9M |
| Dette à Long Terme | 0 | 0 | 0 | 0 | 0 | 0 | $93.1M | $100.6M | $102.5M | $84.7M |
| Passifs Totaux | $331000 | $2.3M | $4.7M | $9.5M | $13.2M | $17.8M | $129.1M | $130.2M | $131.4M | $140.4M |
| Réserves | 0 | -$4.5M | -$23.7M | -$56.7M | -$138.9M | -$245.8M | -$411.5M | -$590.6M | -$650.2M | -$720.1M |
| Capitaux Propres | -$324000 | -$982000 | $38.9M | $26.9M | $206.7M | $221.7M | $76.8M | -$56.5M | -$93.1M | -$95.5M |
| Dette Totale | 0 | $371000 | 0 | $1.0M | $1.6M | $1.4M | $94.2M | $101.4M | $102.9M | $109.7M |
| Dette Nette | 0 | -$516000 | -$42.6M | -$31.4M | -$211.5M | -$231.6M | -$99.6M | $36.2M | $73.1M | $81.2M |
| Fonds de Roulement | -$329000 | -$1.4M | $38.5M | $25.6M | $205.2M | $220.1M | $170.0M | $44.9M | $15.2M | -$9.2M |
Santé financière
| Dette / Capitaux propres | -0.90 |
| Ratio de liquidité | 0.21 |
Rentabilité
| Rentabilité des capitaux propres | 69.92% |
| Rentabilité du capital investi | 1144.58% |
| Rentabilité des actifs | -246.05% |
| Marge brute | 45.28% |
| Marge opérationnelle | -6014.42% |
| Marge nette | -9549.87% |
Entreprises liées: ANVS · BCAB · CELU · EVAX · GBIO · MAIA · MURA
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de BTAI: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions